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Abstract 
Curcumin loaded Ultrasound Contrast Agents for Drug Delivery to Tumor Cells 
Archana Sidalaghatta Nagaraja 
 
 
 
 
 Curcumin (diferuloylmethane) is obtained from Curcuma longa, a rhizome which 
has been used for centuries in traditional Indian and Chinese medicine and diet. This 
hydrophobic phenol has several documented biological and pharmaceutical activities 
(including anti-cancer effects). However, the low solubility and degradation of Curcumin 
at neutral pH limits its therapeutic potential.  Encapsulating the drug in a hydrophobic 
core of a microbubble would prevent the drug from degradation, and permit site-specific 
delivery of Curcumin to tissue.   
 Ultrasound targeted microbubble destruction is a non-invasive method of imaging 
tumors. Ultrasound contrast agents (UCA) are less than 6 µm and can be designed to 
administer drugs. Ultrasound also transiently increases the permeability of cell membrane 
for drug uptake.  
 The microbubbles used for this study range from 1-3 µm and are made of 
surfactant-mixture with a gas core (of perfluorocarbon).  The surfactants were chosen as 
they are shown to overcome drug-resistance of the tumor cells by inhibiting the P-
glycoprotein.  
 The goal of this study was to load Curcumin on surfactant-stabilized 
microbubbles without compromising on the echogenicity and stability of the 
microbubbles. Intrinsic fluorescence was used to quantify the amount of Curcumin 
xiii 
 
loaded into the microbubbles.  Cell studies were also conducted using two breast cancer 
cell lines to study cell-death. 
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Chapter 1: Thesis Aims and Objectives 
The overall goals of this thesis were to load a hydrophobic drug (curcumin) into ultrasound 
contrast agent microbubbles without compromising the acoustic stability of the microbubbles. 
The objectives of the thesis were: 
1. To see the effect of wall constituents of the microbubble on the outcome with respect to 
echogenicity and drug payload. 
2. To see the effect of loading method (solid vs. dissolved drug) in the echogenicity and payload. 
For the first goal, the hydrophilic components were changed, keeping the hydrophobic component 
constant. Microbubbles were prepared  using 3 non-ionic surfactants: Span60, Tween80 and 
Tocopheryl –α-Polyethylene glycol succinate (TPGS). For the first part of the experiments the 
molar ratio of Span 60 was maintained at 80%, and varying ratios of Tween80 and TPGS were 
used. The microbubbles thus formed were named as given (ST68 and SE61 already in use and 
patent-protected). 
Table 1: Nomenclature for microbubbles with varying Tween80 and TPGS amounts. 
Name Span60 Tween80 TPGS 
ST68 80 20 0 
SE61 80 0 20 
STE681 80 10 10 
 
For the 2nd part of microbubble preparation, the molar ratio of Tween-TPGS (hydrophilic 
component) was kept the same and the amount of Span 60 (hydrophobic component) was varied.   
Table 2: Nomenclature for microbubbles with varying span60 amounts.  
Name Span 60 Tween80 TPGS 
80-10-10 80 10 10 
70-15-15 70 15 15 
60-20-20 60 20 20 
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1.2 Loading of curcumin into bubbles 
Different concentrations of curcumin, a hydrophobic drug obtained from the rhizome, Curcuma 
longa, was loaded to the microbubbles using 2 methods:  
1.2.1 Loading drug as solid particles into sonication mixture  
Curcumin was loaded directly into the microbubbles during sonication. The hypothesis was that a 
microbubble has a hydrophobic moiety and hence, a hydrophobic molecule such as curcumin can 
be incorporated into the hydrophobic regions. The hypothesis was that a small molecule would 
also not alter the structure and acoustic stability of the microbubble.  
1.2.2. Loading the drug after dissolving in a suitable solvent 
To overcome problems of improper mixing, surface adsorption to sonicator probe and/or 
glassware, curcumin was solubilized and used for sonication. Some of the solvents in which 
curcumin is soluble are ethanol, acetone, and 0.1N sodium hydroxide (obtained from the 
specifications and properties document of curcumin provided by the manufacturer). Prior to 
finalizing a solvent, 2 ml of each solvent was used with both surfactants and drug. The ideal 
solvent would dissolve curcumin. The microbubbles which were drug-loaded were then checked 
for acoustic stability, drug loading and cell death.  
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Chapter 2: Background and Literature Review 
Ultrasound is a non-invasive and cost-effective mode of imaging tissue abnormalities. Much 
progress has been done in enhancing the image quality from ultrasound especially using contrast 
agents. Drug loaded ultrasound contrast agent represents a new modality of targeted drug delivery 
where the drug is released when the microbubble cavitates in the presence of an ultrasound beam. 
This introduction gives a brief insight into ultrasound principles, imaging techniques used and 
effects of ultrasound. The section also includes an introduction to the drug that is loaded into our 
microbubbles, Curcumin and the documented therapeutic effects and pharmacology. 
2.1 Ultrasound 
2.1.1 History 
The history of ultrasound can be traced back to the 19th century, where sound was used to 
determine the depth of lakes [1]. During this period, Pierre Curie discovered the echo-producing 
capacity of piezoelectric crystals. In the early 1900s, developments in the field of acoustics were 
limited to military applications (development of the hydrophone which is a precursor to SONAR).  
In 1940 Karl Dussik used ultrasound to study the presence of brain tumors (he called the 
technique hyperphonography) and this is the first documented use of ultrasound as a diagnostic 
tool. He hypothesized that since supersonic waves are elastic waves, their interactions with 
particles (cells) would provide information about the micromechanical structure and by studying 
the attenuation of a supersonic beam, biological information could be obtained [2]. Others soon 
followed, and Dr. George Ludwig, Dr. John Wild, and Dr. Ian Donald started using sonography 
to study gallstones, breast-malignancies, and ovarian cysts respectively. In 1950s, Dr. John Wild 
and Dr. John Reid built a linear handheld B-mode instrument for breast tumors and Dr Ian 
Donald performed the first fetal head measurements using ultrasound [1]. After the 1970s, the 
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field of diagnostic ultrasound imaging grew with development of newer techniques such as Power 
Doppler and color Doppler. 
2.1.2 Ultrasound Physics 
Sound waves are mechanical energy transmitted by changes in pressure in a material medium. 
Sound waves are made of high pressure and low pressure pulses traveling through a medium 
(Figure 1). When the frequency of the sound waves is greater than 20 kHz (the upper-limit on the 
audible range for humans), it is called ultrasound. Ultrasound has many uses besides medicine, 
but has become the mode of choice when convenient, non-invasive imaging of tissue is necessary. 
 
Figure 1: Compression and rarefaction of air molecules due to a sound wave . 
The ability of ultrasound to detect changes in tissue density (as in the case of solid tumors) is a 
result of many factors. Some of the parameters are the wavelength, speed and energy (related 
terms are power and intensity) of the sound wave. For imaging and in-vivo modalities, the most 
important parameter is the speed of sound wave. Speed depends of the medium in which the wave 
is travelling, specifically by the density of the medium and the stiffness given by the following 
equation.  
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Where k is the stiffness and ρ is the density. Tissue with high stiffness and density such as bone 
will have a higher speed than a soft, rubbery tissue such as fat (as increase in k increases c). In 
conventional B-mode imaging, a single average of 1540 ms-1 is used for imaging tissue without 
significant error [3].  
Wavelength (λ) is dependent on the speed of sound, and is given by the equation,  

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where f is the frequency. Knowing the frequency of an ultrasound wave, it is possible to calculate 
the wavelength (in soft tissues, it turns to be 0.1-1mm). Wavelengths are extremely important for 
ultrasound imaging as this determines the resolution of the image. 
Another term that is often used in ultrasound imaging, especially for B-mode imaging (which is 
an image built from the reflection of an ultrasound wave on tissue) is acoustic impedance (z). It is 
a term similar to resistance in an electric circuit, and is an indication of how the particles respond 
to a pressure wave. This is also dependent on stiffness and density and given by the equation, 
	 
 =  =  √() 
When a sound wave passes from one medium to another with different acoustic impedance, an 
extra wave is formed that is reflected at the interface. The pressure of reflected wave (pr) is 
related to impedances (z1 and z2) and pressure of the incident wave (pi) by the equation, 
 

=  
2 − 1
2 + 1
 
The ratio of the intensity will be the square of the above equation.  
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When an ultrasound wave travels through tissue, some energy is lost, and this loss is called 
attenuation. Attenuation in tissue is a function of tissue depth (intensity decreases with distance), 
scattering and absorption of sound energy. Absorption of ultrasound energy occurs when an 
oscillating particle in the medium generates heat and this effectively reduces the strength of the 
signal incident on the tissue.  
2.1.3 Diagnostic Ultrasound  
Diagnostic ultrasound works in the range of 1-MHz to 20-MHz [3]. Frequencies as high as 50-
MHz are used clinically [4]. In diagnostic ultrasound, these pressure variations are produced by a 
transducer. In most cases, the transducer also acts as a receiver that picks up the reflected waves 
converting them back into electrical signals. The reflected waves are then recreated to obtain an 
image. This is called B-mode imaging (other modes are M-mode for ‘motion’ mode and A-mode 
for amplitude mode). Contrast agents such as those mentioned in the thesis are used regularly to 
enhance contrast, and the next section deals with contrast agents and their uses for drug delivery. 
 
Figure 2: Commercial Ultrasound Transducers from GE Healthcare 
(http://www.gehealthcare.com/usen/ultrasound/products/transducers.html) . 
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2.1.4 Contrast Agents 
Although the discovery of a contrast agent was serendipitous [5], it was soon seen that air bubbles 
do not last long enough for imaging. Hence, the concept of contrast agents developed. Contrast 
agents are mostly microbubbles that are used to make organs and tissue, cavities easier to 
visualize due to their high contrast against the tissue [6]. These primarily consist of air or an inert-
gas that is encapsulated within a polymer or protein shell. As small as 3 µm in diameter, these 
produce excellent images due to an impedance mismatch at the gas/tissue interface. The size of a 
contrast agent is 1000 times smaller than the wavelength of an ultrasound wave, but it can be 
made to resonate at the ultrasonic frequency. This resonant frequency of the bubble increases as 
the diameter decreases (case of each microbubble type). When they resonate at the ultrasonic 
frequency, the images are greatly enhanced even at higher dilutions. This means that smaller 
quantities can still be used for sharp imaging [7]. In addition, contrast agents are also used for 
harmonic imaging where the 2nd harmonic is used to distinguish the agent from tissue.  
2.1.5 Contrast Agents as Drug Delivery Vehicle 
Contrast agents can be destroyed in the presence of an ultrasound beam. This has been used to 
design drug delivery vehicles especially for tumor therapy where highly cytotoxic drugs are 
delivered to the tumor only. Besides controlling the distribution of drug among tissue, this can be 
used to enhance bioavailability of insoluble drugs. The drugs used commonly along with contrast 
agents for drug delivery are doxorubicin and paclitaxel. Ligands can also be attached to enable 
specific binding, imaging and drug-delivery in a single contrast agent.  
A contrast agent developed in our lab can deliver doxorubicin to tumor cells without adversely 
affecting normal cells [8]. This can greatly decrease toxicity of doxorubicin which is highly 
cardiotoxic. Paclitaxel is another drug that is highly hydrophobic, and hence needs to be 
solubilized before administration. A contrast agent developed in our lab (unpublished results) can 
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effectively encapsulate paclitaxel in its hydrophobic core and deliver it selectively to tissue in the 
presence of ultrasound energy.  
When a continuous beam of ultrasound is incident on cells, effects of ultrasound on cells depend 
on the energy. In case of tumor cells, high intensity beams are proven to inhibit DNA repair and 
replication, whereas low intensity beams do not have such inhibitory effects [9]. Due to the 
thermal effect of ultrasound, increased cytotoxicity is seen for doxorubicin when ultrasound is 
used as adjuvant [10]. This increased cytotoxicity can be related to an increase in cell 
permeability due to presence of ultrasound [11].  
2.2 Surfactants Used 
The surfactants used to prepare the microbubbles are briefly described below. Some of the 
surfactants are used in the same molar quantities as mentioned in previous literature published by 
our lab and the patent protecting the same [12-13]. TPGS is a new vitamin-E conjugated PEG 
surfactant that has been used successfully in our lab to make microbubbles. The properties and 
advantages of each surfactant are summarized in this section. 
2.2.1 Span 60 
Span 60 (sorbitan monostearate) is an ester of sorbitan and stearic acid. It is a food grade 
emulsifier that is widely used in making bread, confectionery, cakes and whipped cream (Figure 
3) and is approved by the FDA for [14]. It is a white solid (small spheres) and is insoluble in cold 
water. In a study done on rats, the toxicity of span 60 was studied, and it was seen that 0.4-5% of 
span 60 delivered through the diet does not cause any toxicity to the rats [15]. The only noticeable 
organ changes were liver enlargement and increased nephrosis. Span 60 is used to make micelles, 
niosomes [16] and organogels (intra-muscular) [17] for delivery of therapeutics. 
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Figure 3: Structure of Span 60 (obtained from the Sigma-Aldrich website (Product ID: S7010)). 
2.2.2 Tween 80 
Tween 80 or polysorbate 80 (Figure 4) belongs to a family of non-ionic surfactants which is 
widely used in food and pharmaceutical industry. It is a viscous liquid with HLB (hydrophilic-
lipophilic-balance) of 15 and it is soluble in water. It is used as an emulsifier and dispersing agent 
in medicinal preparations and emulsifier and defoaming agent in food industry [18]. Like span 60, 
Tween 80 is also considered safe and is approved as a food additive by the FDA [14] based on 
their safety record, Tween 80 is also approved for use in parenteral products. It is widely used as 
a lipophilic solvent in drug formulations and hence, its effects on biological systems are fairly 
well studied.   
 
Figure 4: Structure of Tween 80 (obtained from Sigma-Aldrich website (Product ID P1754)). 
Studies have been conducted in which interaction between Tween 80 and several life forms (such 
as bacteria and fishes), as well as pharmaceutically relevant proteins have been documented. One 
of the advantages of using Tween 80 is that it has been proven to overcome drug resistance. In a 
study done by Woodcock et al, Tween 80 was found to reverse drug resistance by modulating the 
MDR phenotype at 1:104 concentrations of Tween 80 to media [19]. The same study also 
concluded that the presence of polyethylene oxide hydrophilic moieties was able to reverse MDR 
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(to include other surfactants such as TPGS, Brij series). Etoposide (an anti-cancer drug used for 
solid tumors) was used to study how Tween 80 can overcome drug resistance in adriamycin-
resistant leukemia cell line [20]. Presence of Tween 80 was shown to increase sensitivity of cells 
to the drug. On account of its safety, Tween 80 has also been used to deliver drugs to brain. 
Coating Tween 80 on nanoparticles resulted in increased amounts crossing the blood brain barrier 
[21].  
2.2.3 TPGS 
D-α-tocopheryl-polyethylene-glycol-1000 succinate (TPGS) is a non-ionic surfactant that is also 
widely used as a food additive and pharmaceutical agent.  TPGS is synthesized from the lipid-
soluble antioxidant, α-tocopherol (vitamin E) by grafting to a polyethylene glycol (PEG) 1000 
oligomer through a succinate diester linker. Of the 3 surfactants used for making the 
microbubbles, this is most relevant clinically.  TPGS 1000 (used to prepare microbubbles) has 
been approved by FDA as a drug solubilizer in oral [22], parenteral [23], topical [24], nasal, and 
rectal/vaginal therapies [25]. It is a white waxy solid that is soluble in water (1g/10mL) and has 
an HLB of 13. It provides a water-soluble form of vitamin-E and has been used as a dietary 
supplement. It is used to reduce drug sensitivity and increase drug bioavailability [26]. 
 
Figure 5: Structure of  TPGS (obtained from Sigma-Aldrich website (Product ID: 57668)). 
TPGS is used to prepare polymeric formulations along with a number of other polymers such as 
PLGA (poly(lactic-co-glycolic acid)) [27], PCL (Polycaprolactone) and is also used as a 
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dispersant for carbon nanotubes [28]. It is also widely used for encapsulation and delivery of 
hydrophobic drugs like paclitaxel [29]. Like Tween 80, TPGS also has a PEG chain that is 
instrumental in the surfactant’s ability to modulate p-glycoprotein [30].  It has been conjugated to 
other cytotoxic drugs such as doxorubicin [31] to minimize drug toxicity and/or for targeted 
delivery.  
2.2 Curcumin 
Curcumin (diferuloylmethane) is obtained from turmeric (Curcuma longa L.) a perennial plant 
with branched yellow-brown rhizomes (from which the drug is extracted) [32] (Figure 6). 
Turmeric is a well-documented spice, preservative, and medicinal herb in India and China, and is 
indigenous to the Indian subcontinent [32-37].  The medicinal properties of turmeric are 
explained in an excellent review by Chattopadadhyay et al [32]. In brief, traditional Indian 
medicine uses turmeric for wound healing, inflammation, preventing hair growth, abdominal, 
hepatic and biliary disorders, whereas turmeric in Chinese medicine is used primarily for 
abdominal ailments [34]. Turmeric is an FDA-approved food additive in the United States [38] 
and according to the Food and Agriculture Organization over 2400 metric tons of turmeric are 
imported annually into the USA for consumer use in 2005 [39]. Turmeric has proteins, 
carbohydrates, essential oils, and moisture but the most important pharmaceutical agent from 
turmeric are  curcuminoids (3-5%) (Figure 7)  [40]. Curcuminoids give the characteristic yellow 
color to turmeric and curcumin, the primary curcumoid is responsible for most of the therapeutic 
effects [33]. Curcumin is extracted from turmeric by solvent extraction. Powdered turmeric is 
dissolved in a suitable solvent (such as ethanol, acetone, or methanol) and solvent is partially 
evaporated. The concentrate is then cooled to allow curcumin to crystallize. After a wash with 
solvent such as hexane, impurities are removed and residual solvent vaporized to obtain yellow 
crystals of curcumin [41]. 
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Figure 6: a) Turmeric Rhizome; b) Plant; c) Curcumin structure [42] 
2.2.1 Chemistry  
Curcumin was first chemically characterized in 1910. Chemically, curcumin is bis-α,β-
unsaturated β-diketone (diferuloylmethane) which exists in a keto-enol tautomerism where keto is 
predominant in neutral and acidic pH and stable-enol form is in alkaline pH [43]. It is a 
hydrophobic phenol that is insoluble in water, but soluble in acetone, DMSO and alcohol. At pH 
3–7, curcumin acts as a potent H-atom donor and at alkaline pH, curcumin acts mainly as an 
electron donor.  
Curcumin has a molecular weight of 368.37 and a melting point of 183°C. Commercial grade 
curcumin (from Sigma Aldrich) has 70% curcumin, 10-20% of demethoxycurcumin and less than 
5% of debismethoxycurcumin (Figure 7). Commercial grade curcumin is known to have 
comparable inhibitory effects on carcinogenesis as pure curcumin. This can be attributed to the 
pro- and anti-oxidant capacities of both the analogs of curcumin [44-45] . 
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Figure 7: Structures of Curcumoids [45] 
High performance liquid chromatography (HPLC) has been used to study the degradation of 
curcumin at various pH. In a detailed study done by Wang et al [46], curcumin degradation was 
found to occur by apparent first-order kinetics. It was also seen in the same study that 90% of 
original curcumin degraded at 37°C in 30 min and 0.1M phosphate buffer. Curcumin was also 
found to degrade rapidly in serum-free medium, but less than 20% degraded when 10% FBS was 
added to the media. Vanillin (major degradation product), ferulic acid and feruloyl methane were 
found in HPLC analysis [46]. Vanillin is a known antimutagenic for bacterial and mammalian 
cells [47] and hence, the degradation product of curcumin also has therapeutic potential.  
Curcumin is extremely photosensitive and degrades rapidly in the presence of sunlight. Hence, 
most preparations of curcumin are done in amber-colored glassware to limit exposure to light 
(solvent system also affects stability) [48]. Curcumin exhibits photo-cytotoxicity probably due to 
the generation of reactive oxygen species upon irradiation [49]. Curcumin exhibits absorption in 
UV–vis region in the range from 408 to 434 nm [50]. In most polar solvents such as methanol and 
14 
 
DMSO, the absorption spectrum is broad, but has a  peak  of 420 nm. Curcumin also exhibits 
florescence and detailed investigations into the florescent properties of curcumin in various 
solvents have been conducted (Figure 8). The Stokes’ shift is found to vary dramatically with the 
solvent chosen (2000 to 6000cm−1, 30–140 nm). Binding of curcumin to proteins such as HSA 
[51] and inclusion in liposomes and cells [52] also affects fluorescence. An excellent review on 
the molecular basis of curcumin’s photochemical properties is given by Priyadarsini [50]. 
 
Figure 8: Absorbance (left) and fluorescence (right) of curcumin in various solvents. (a) chloroform, 
(b) acetone, (c) methanol (d) HSA, (e) Phosphotidylcholine liposomes and (f) EL4 cell line [50] . 
2.2.2 Pharmacology 
Curcumin has a number of therapeutic effects (described in the following sections) but the 
bioavailability of curcumin is low. Curcumin is relatively non-toxic and upto 100 mg is included 
in Indian and Chinese diets every day. Phase 1 clinical trials have shown that up to 8g of 
curcumin can be tolerated without any toxic effects [53]. However, curcumin is still not approved 
as a therapeutic, and it is widely believed that the limited bioavailability is the main concern [54]. 
When taken orally, curcumin is known to undergo extensive first-pass metabolism in the liver and 
this has been proven in both animal and human studies. Radio-labeled curcumin was administered 
to Winster rats and the concentration of curcumin in feces and tissue was quantified [55]. There 
was a dose dependent radio-activity in tissue and it peaked at 30 minutes. In the above study, 
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percentage of curcumin absorbed was constant at 66%. Studies done on both humans and rats 
indicated the degradation of curcumin is by extensive conjugation and reduction and is more 
intensive in rats than in humans [56]. When injected intravenously or intraperitonially, it 
undergoes reduction that leads to the formation of tetrahydrocurcumin, hexahydrocurcumin and 
octahydrocurcumin (Figure 9) [57].  
 
Figure 9: Curcumin, analogs and degradation products [57]. 
Low bioavailability of drugs can be attributed to low activity, low absorption and/or rapid 
metabolism. In a comprehensive review of problems regarding bioavailability, Anand et al., list 
the distribution of curcumin at various doses in both animals and humans, via various routes [54]. 
It is unclear whether the various metabolites have any therapeutic activity, and hence preventing 
the degradation by encapsulation, increasing absorption become important. Curcumin is absorbed 
better when taken with piperine, a component of pepper [58], other methods used are solid 
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nanoparticles, encapsulation within phospholipids and PLGA (poly(lactic-co-glycolic acid)) 
nanoparticles [59].  
An exhaustive list of molecular targets of curcumin is available [35, 54, 57] and the reviews on 
pharmacological effects also give a brief insight into the various diseases for which curcumin is 
seen to have a therapeutic value. The following sections will focus on therapeutic potential of 
curcumin in cancer and other diseases. 
2.2.3 Therapeutic Potential of Curcumin in Cancer 
Curcumin is known to be an inhibitor of angiogenesis [60] and induce apoptosis [61] in breast 
cancer cell lines.   
2.2.3.1 Breast Cancer 
The National Cancer Institute (NCI) defines cancer as a term for diseases characterized by an 
abnormal growth of cells that can potentially invade other tissue. The American Cancer Society 
(ACS) predicts that an estimated 200,000 new cases of invasive breast cancer and 50,000 cases of 
in-situ breast cancer will occur during 2010 [62]. ACS also predicts that approximately 40,000 
people will die from breast cancer in 2010. However, there has been a decreasing trend in the 
number of cases of breast cancer, and this can be attributed primarily to early detection and better 
treatment methods [62].   
Detection of tumors of the breast is done by magnetic resonance imaging, mammography and/or 
ultrasound [63]. Currently ultrasonography is used in conjunction with mammography for 
detecting breast cancer and ultrasound can detect 3-4 more breast cancers per 1000 women 
especially for the high risk categories. Ultrasound is also useful in distinguishing cysts from solid 
tumors and benign from malignant tumors [64]. Ultrasound is also the recommended method of 
imaging for younger patients under the age of 30 [65].  Recent developments in molecular 
imaging in cancer, has made it possible to detect abnormalities in tissue using ligands, and deliver 
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drug to tumor sites only [66-67]. Hence, ultrasound mediated drug delivery is a viable choice for 
breast cancer. 
Cancer cells are quite different from normal cells, and there are a number of ways in which 
curcumin is known to interact with tumor cells. This section briefly explains the phenomena and 
the section following this explains how curcumin works in each scenario. 
2.2.3.2 Tumor Microenvironment 
There are certain differences in microenvironment during normal growth and tumor growth. A 
characteristic feature of tumor microenvironment containing solid tumors is decrease in 
extracellular pH, oxygen and nutrient concentrations [68].  As the tumors grow, the cells further 
from the capillary network are oxygen and nutrient deprived, as these are diffusion driven 
processes. There is also evidence that under such hypoxic conditions, the cells switch to oxygen-
independent glycolysis, producing lactate in high quantities at lower efficiency than the TCA 
cycle. The decrease in energy production is also associated with 1) collapse of Na+ and K+ 
gradients, 2) depolarization of membranes, 3) cellular uptake of Cl−, 4) cell swelling, and 5) 
decreased cytosolic pH, resulting in intracellular acidosis in tumor cells [69]. The factors that 
make tumor hypoxia important from a drug-delivery standpoint, is that it increases genetic 
instability [68] and progression towards metastasis [70]. Chronically hypoxic cells (furthest from 
capillaries) are known to survive and grow into a more clinically aggressive phenotype whereas 
the acute hypoxic cells (closer to capillaries) would cause ROS (reactive oxygen species) related 
tissue damage. In addition, the availability of  drugs decreases as the tumor is further from the 
capillary, because drugs will not be able to reach the tumor site (common chemotherapetutic 
drugs such as cyclophosphamide, carboplatin, and doxorubicin are also known to be oxygen 
dependent). A transcription factor called hypoxia-inducible factor (HIF) is known to protect the 
cell from apoptosis by modulating several proteins [71]. In the Figure below, a section of human 
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colon cancer has been treated with an antibody for endothelial cell marker CD31 (shown in 
green) and a hypoxic marker, pimonidazole (shown in red) is used to indicate hypoxic cells. For 
this experiment, secondary antibodies which were conjugated to fluorescent proteins gave the 
corresponding color [72]. 
 
Figure 10: Hypoxia in a solid tumor. See text for details [72]. 
2.2.3.3 Angiogenesis 
One way in which tumor cells counter the problem of hypoxia is to physically increase the blood 
supply. This is accomplished by formation of new blood vessels by angiogenesis. The tumor 
vasculature that is formed thus, is characterized by vigorous and chaotic proliferation that leads to 
immature, structurally defective, and ineffective microvessels [73]. Tumor vasculature is ‘leaky’ 
due to abnormalities in endothelial cells, interendothelial junctions and/or basement membrane. 
The heterogeneity also depends on the type of organ and the presence of angiogenic regulators 
such as VEGF [74]. While the theory that angiogenesis leads to metastasis remain controversial 
[75], angiogenesis provides a good option for treating tumors. Some of the advantages of 
angiogenesis as a treatment option are: a) it is targeted to a process that is specific to tumors (does 
not harm normal cells) b) usually directed to the endothelial cells (hence, drug penetration is not 
an issue) c) possible to repeatedly administer drugs (Figure 11) [76]. High microvessel density is 
a successful predictor of metastatic risk because high density (Weidner’s method) increases the 
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area of the vascular surface, facilitating the escape of tumor cells into the circulation [77]. In an 
excellent review by Gasparini, several angiogenetic markers are listed for prognosis and 
treatment of breast cancer [78]. Curcumin is known to be anti-angiogenic in some cell-lines such 
as MDA-MB-231 breast cancer cell line by modulating cell transcription factors such as VEGF 
and NF-Kβ (nuclear factor kappa-light-chain-enhancer of activated B cells is a protein which 
controls transcription and its incorrect regulation is related to cancer). 
 
Figure 11: A) Normal chemotherapy B) Directed for anti-tumor angiogenesis [76]. 
2.3.3.3 Apoptosis 
Apoptosis is a process that is intimately associated with normal tissue and is vital for 
homeostasis. Commonly called the “programmed cell death”, changes in apoptotic control is 
crucial to progression of a tumor. There are 2 important genes/gene products that are implicated 
in apoptosis, p53 gene (which is tumor-suppressor gene) and bcl-2 gene (which is anti-apoptotic) 
[79]. P53 gene is a crucial gene that is involved in DNA repair and changes in this gene are 
implicated in 50% of all tumors [80] (most p53 mutations observed in breast cancer are of 
somatic origin). The best characterized function of p53 gene is as a transcription factor. The gene 
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product is a protein that is generally rapidly degraded by a proteosome, but in response to cellular 
stress, the post-translational modification prevents degradation. Restoring the expression of p53 
gene is seen as a potential therapeutic strategy [81].  Another mode of cell death that is seen in 
some cell death is paraptosis. Paraptosis differs from apoptosis in many ways. Morphologically, 
the cells do not show apoptotic bodies or nuclear fragmentation. There is also no caspase related 
activity and internucleosomal DNA fragmentation is absent [82]. These two methods are 
important as curcumin is known to kill some breast cancer cell lines by apoptosis (MCF-7) and 
some by paraptosis (MDA-MB-231). 
2.2.3.4 Drug Resistance 
Another problem that complicates cancer therapy is multidrug resistance where tumors develop 
resistance to therapy. It can be extrinsic, where exposure to one cytotoxic agent develops a cross-
resistance to a range of similar compounds, or it can be an intrinsic property of the tumor tissue 
[83]. Intrinsic or extrinsic, it poses a huge problem in treating and killing the tumor. The main 
proponent of this multidrug resistance is a protein called the p-glycoprotein (p-gp) encoded by 
MDR1 gene. This protein is an ATP-dependent efflux pump that selectively pumps cytotoxic 
drugs out of the cell and is widely expressed in human cancer cells [84].  Several reviews 
elaborate the mechanisms by which this glycoprotein hinders therapy [84-86] but what is also 
important is how more research is directed towards applying this knowledge towards 
circumventing the problem of drug resistance (Figure 12). The surfactants and the drug chosen 
are all known to overcome drug resistance. 
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Figure 12: P-gp modulated drug efflux [83]. In the presence of ATP, the p-glycoprotein can pump 
drugs out of the cell into extra-cellular space. 
2.2.3.3 Curcumin in Cancer  
The previous section briefly introduced some phenomena seen in tumor cells and their 
microenvironment. This section explains how curcumin is used to kill or inhibit the growth of 
tumor cells.  
In the tumor microenvironment, the pH is lower than 7 (acidic) and curcumin is insoluble but 
stable at this pH. Curcumin is stable at acidic pH but unstable at neutral and basic pH, under 
which conditions it is degraded to ferulic acid and feruloylmethane (which have lower activity 
than curcumin) [46]. Although degradation is considerably lower in blood and serum, curcumin 
degradation is extremely low in pH 1-6 [35] and hence, targeted delivery of intact curcumin at the 
tumor site where the pH is ideal for maximum activity is desired. It must be noted here, that 
owing to the unstable nature of curcumin, several analogues are currently being researched. One 
of the natural analogues and curcumin metabolite is tetrahydrocurcumin (THC) (Figure 13) which 
has more anti-oxidant activity but is less potent in reversing drug resistance [87]. 
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Figure 13: Left: Structure of tetrahydrocurcumin (THC) [87]. Right: THC in powder form [35]. 
Curcumin is known to prevent the transformation, proliferation and invasion of tumor cells. 
Lower incidences of colon cancer are seen in ethnic cultures that consume turmeric regularly 
[88]. Curcumin has many molecular targets specific to tumor cells, but the most widely studied 
are the molecular targets relevant to apoptosis, angiogenesis and drug resistance.  
Induction of apoptosis by curcumin is particularly well studied in colon cancer [89], ovarian 
cancer  and breast cancer cell lines [61, 90]. Several molecular targets have been identified for 
curcumin in tumor cells and hence, there is more than one theory on how curcumin causes 
apoptosis, especially in breast cancer cells. Kunwar et al, studied the cellular distribution of 
curcumin in normal and tumor cells [91]. Using confocal microscopy, they found that in MCF7 
cells, curcumin was distributed in the cell within 2 hours of administration. Using sub-cellular 
fractionation they found that curcumin was differentially distributed with maximum amounts in 
the membrane. Zhou et al, also studying effect of curcumin on MCF-7 cells found that curcumin 
inhibits cell proliferation in a dose and time dependent manner and correlated that to protein-
kinases signaling [92]. Studies involving mechanisms of apoptosis of MCF7 cells include Bax 
protein expression [61], microtubule instability [93], caspase-dependent PARP (Poly(ADP-
ribose) Polymerase) cleavage [94] and inhibiting NF-KB [95].  For estrogen-negative breast 
cancer cell line such as MDA-MB-231, the effects are more anti-proliferative than apoptotic. 
Curcumin concentrations as low as 5 µg/ml has been found to down-regulate MMP-1 mRNA, 
reduced NF-KB and cyclin-D expression [96]. Another group used different concentrations of 
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curcumin (5-30 µg/ml) to induce apoptosis in MDA-MB-231 cells and they reported decrease in 
cell viability, increase in cell-arrest in G2/M phase, increased expression of p21 and bax and 
decreased expression of NF-KB and p53 over a 48-hour period (Figure 14) [97].  
 
Figure 14: Effect of curcumin on MDA-MB-231 cells [97]. 
In their paper, Duvoix et al have shown that curcumin can inhibit the expression of a glutathione 
S-transferase (GSTs) enzyme. These enzymes are known to confer drug resistance by providing a 
mechanism for the cell to eliminate drugs, and this is seen widely with estrogen-positive MCF-7 
cells [98]. Drug-sensitive and drug-resistant cervical carcinoma cell lines were used to study how 
curcumin overcomes drug-resistance [99]. The drug resistant cell line showed increased p53 
expression that decreased with time when concentrations of 1-30 µM of curcumin was used. 
Concentrations of 35-100 µM caused cell-death after 3 days. The same study also used 
vinblastine (an antimicrotubule drug used to treat cancers) with curcumin concentration on 20 µM 
increase cytotoxicity.   
MDA-MB-231 is a highly metastatic breast cancer cell line and several studies using matrigels 
and collagen matrices have indicated how cell migration can be prevented by curcumin. The cell 
invasion was studied for varying concentrations of curcumin (0-50 µM) and it was found that 
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increasing concentrations decreased cell migration (Figure 15) [100]. Anti-metastatic activity of 
curcumin has also been studied in lung cancer cell-line (A579 cell line) and these studies indicate 
decreased lung-tumor nodules and increased survival of animals [101]. A recent study on the 
effects of curcumin by Yoon et al, showed that induction of cell death in MDA-MB-231 cells are 
due to a process called paraptosis, characterized by swelling and fusion of mitochondria and 
endoplasmic reticulum resulting in vacuolation [95].  
 
Figure 15: Inhibition of cell-invasion in a matrigel with varying concentrations of curcumin [100]. 
VEGF, a known marker which is vital for angiogenesis and tumor growth is over-expressed in 
many tumor cell lines. Curcumin is an inhibitor of VEGF in MDA-MB-231 and NIH3T3 tumor 
cell lines [102]. Studies done using implanted pancreatic tumor cells and ovarian cancer into nude 
mice show that curcumin works by a mechanism similar to that of avastin (humanized 
monoclonal antibody approved by FDA, VEGF-inhibitor) [103].  
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Chapter 3: Materials and Methods 
3.1. Material 
3.1.1. Polymers 
Three non-ionic surfactants were used for preparing the microbubbles. Span60 (sorbitan 
monostearate) (S7010, lot #010M0128) and tween80 (Polyethylene glycol sorbitan monooleate) 
(P1754, lot #018K00941) were purchased from Sigma Aldrich (St. Louis, MO) and used without 
further purification. NF grade TPGS (batch# 78971100) was bought from Eastman and used 
without further purification. 
3.1.2. Drug 
Curcumin powder (70%) (C1386, lot # 079K1756) obtained from Curcuma longa was purchased 
from Sigma Aldrich (St. Louis, MO) and used without further purification. 
3.1.3. Cell Lines 
Human breast adenocarcinoma cells (MDA-MB-231) (passage 8-10) and MCF-7 (passage 17-19) 
were purchased from ATTC (Manassas, VA). 
 
3.1.4. Cell Culture Materials 
RPMI-1640 medium (containing 2 mM Lglutamine, 10 mM HEPES, 1 mM sodium pyruvate, 
4500 mg/L glucose, and 1500 mg/L sodium bicarbonate) ( lot#10040461CV)was purchased from 
Cellgro, Mediatech Inc (Manassas, VA) and used without further modifications. Dulbecco’s 
Modification of Eagle’s Medium (DMEM) (1X containing 4500 mg/L glucose without 
Lglutamine) (lot# 15013261CV) was purchased from Mediatech Inc (Manassas, VA). Trypsin 
EDTA (lot# 25053244) and fetal bovine serum (FBS) (lot# AUJ35775) were purchased from 
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Fisher Scientific (Springfield, NJ).  Penicillin/streptomycin antibiotic (lot# 096K2421) was 
purchased from Sigma Chemical Co., St. Louis, MO. LIVE/DEAD® Reduced Biohazard 
Viability/Cytotoxicity Kit #1 (L-7013, lot# 501074) was purchased from Invitrogen  (SYTO® 10, 
a green fluorescent nucleic acid stain labels all cells and DEAD Red labels only cells with 
compromised membranes).  
3.1.5. Other Chemicals 
Octafluropropane (99% min) was purchased from American Gas Group (Toledo, OH) and used 
after passing through a 0.22 µm filter (Nalgene, Rochester, NY). Phosphate buffer saline (0.1M) 
was used as the buffer for preparing and testing the microbubbles after filtration using a 
membrane-filter (0.2 µm from Millipore). Sodium chloride, potassium chloride, sodium 
phosphate dibasic and potassium phosphate monobasic were all cell-culture tested and obtained 
from Sigma Aldrich (St. Louis, MO). D-glucose (used for freeze-drying the microbubbles), 
sodium hydroxide pellets, 100% ethyl alcohol, isopropanol and DMSO (dimethylsulfoxide) were 
obtained from Sigma Aldrich (St. Louis, MO).  
3.2. Ultrasound Contrast Agent Preparation  
Ultrasound contrast agents were prepared as previously published by our lab (US patent 
#5,352,436) with slight modifications [12].  
3.2.1. Microbubble Preparation  
The detailed standard operating procedure for preparing surfactant microbubbles is included in 
the appendix B. In brief, calculated amounts of surfactants were taken in 50 ml of PBS. The 
mixture was then autoclaved for 30 min to decrease the particle size of span 60 (surfactant 
mixtures containing TPGS were heated prior to autoclaving). The mixture was then cooled with 
continuous stirring to enable proper mixing of the surfactants. The cooled mixture was then 
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sonicated continuously for 3 min at 110 W using a 0.5 inch probe horn (Misonix Inc. CL4 tapped 
horn probe with 0.5″ tip, Farmingdale, NY) in an ice bath. The solution was purged with 
octofluoropropane before and during sonication. The microbubbles were then separated from the 
mixture using separation funnels with 3 washes using cold PBS (4°C) every 30 min. In each 
wash, 3 layers are formed, and the bottom layer was discarded. The intermediate layer that forms 
after the 3rd wash was collected as the microbubble fraction. This was diluted 1:1 with PBS at 
room temperature and formed the working solution for all experiments. 
3.2.2. Freeze Drying Microbubbles 
Microbubbles obtained from regular preparation were freeze-dried using a procedure published 
by our lab [104]. In brief, 2 ml of undiluted microbubbles were taken in 15 ml lyophilization vials 
(West Pharmaceutical Services, Lionville, PA) using special pipette (Gilson Pipetman, 
Middleton, WI) for viscous liquids. 2 ml of glucose in PBS was then added to the microbubbles 
and the vials closed to the first groove Flurotec® lyophilization stoppers (West Pharmaceutical 
Services) stoppers. The vials were flash-frozen in liquid nitrogen for 5 min. This was then freeze-
dried on a Virtis Benchtop freeze-dryer (Gardiner, NY) for 12-14 hrs on a chamber that was 
previously kept at -80°C (temperature was -76.5°C and pressure was 17-20 µBar). Prior to 
removing the samples, the vials were sealed using a piston that was lowered. The freeze-dried 
mixture thus obtained was further sealed with parafilm tape till further use. PFC gas was injected 
into the mixture using a sterile syringe immediately after removing from the freeze-drier.  The 
sealed vials can be used after resuspending the mixture in equal amounts of DI water. 
3.3. Drug Loading Method 
Curcumin was loaded in 2 methods for all microbubbles prepared: a) direct loading of solid drug 
using intact curcumin and b) solubilized curcumin. 
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3.3.1. Direct Loading 
For direct loading, 100 µM, 250 µM and 500 µM drug concentrations were used. This 
corresponds to 1.86 mg, 4.6 mg and 9.2 mg of curcumin in 50 ml of surfactant mixture. Curcumin 
was weighed out in micro-centrifuge tubes and covered by foil till sonication. The drug was 
added to the surfactant mixture directly and sonicated after gentle stirring. The microbubble 
preparation protocol was not modified and microbubbles collected were stored in Vacutainers  
(Becton Dickinson, Rutherford, NJ) at 4°C till further use. 
3.3.2. Loading After Solubilization 
For solubilizing curcumin, a number of solvents were considered including ethanol, acetone and 
sodium hydroxide (NaOH).   
Although the MSDS mentions solubilizing curcumin in 0.5M NaOH, 1 ml of 0.1M NaOH was 
used to solubilize the drug as alterations in pH of the surfactant mixture was undesirable (the 
current protocol produces bubbles at physiological pH and effect of pH on microbubbles has not 
been documented). Three different concentrations of drug were again used (100 µM, 250 µM and 
500 µM) similar to the first method. The drug was dissolved in sodium hydroxide just prior to 
sonication to minimize the degradation of curcumin in the alkaline solution. The deep-red 
solution of NaOH was vortexed and immediately added to 50 ml of the surfactant mixture and 
was sonicated. The solubility of curcumin in NaOH was concentration dependent and at 500 µM, 
curcumin required a slightly longer time to dissolve completely (about 1-2 minute longer). The 
microbubble preparation procedure was unaltered and collected microbubbles were stored in 
Vacutainers till further use. 
The legend used for all tables and Figures for drug loading as follows. Each drug-loaded 
microbubble has a number-alphabet format. 1, 2 and 3 corresponds to 100 µM, 250 µM and 500 
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µM initial curcumin concentrations. Alphabets S and D have been used to indicate solid particle 
loading and dissolved drug respectively. 
3.4. Contrast Agent Characterization and Drug Loading 
The regular and the drug loaded microbubbles were tested for their acoustic properties using dose 
and time responses. A 1:1 dilution of the collected microbubbles in PBS was used as the working 
solution. All measurements were repeated 3 times with independent trials for each sample. 
3.4.1. Size Analysis  
The size of the microbubbles collected was analyzed using a Zetasizer nano ZS (Malvern Inst., 
Worcestershire, UK). 50 µL of microbubbles were dispersed in 950 µL PBS in tapered cuvettes 
for size-analysis. For each sample, the z-average was noted for the diameter of microbubbles and 
summarized.  
3.4.2. Dose and Time Response 
For in-vitro acoustic testing of microbubbles, 50 ml of PBS at 37°C was taken in a custom vessel 
made of acrylic plastic. This vessel has an acoustic window of approximately 1.5 in X 1.5 in.  A 
stir-bar was also used to continuously stir the PBS solution. This vessel was placed in another 
cubical tank that is filled with 20 gallons of DI water and temperature controlled to 37°C. A 
single Panametric (Waltham, MA) 5 MHz transducer (12.7 mm diameter, -6dB bandwidth of 
91% and focal length of 50.8 mm) connected to a digital oscilloscope (LeCroy 9350A, LeCroy 
Corporation, Chestnut Ridge, NY) and a computer with LabView 7.1 (National Instruments, 
Austin, TX) is also placed in the tank and focused to the sample through the window. Peak 
positive and negative pressures were measured at 0.69 MPa and 0.45 MPa using a 0.5 mm 
polyvinylidene fluoride needle hydrophone (Precision Acoustics, Dorset, UK).  
For each dose response, samples were pipette into the vessel with increments of dose and the 
amplification read at 40dB. The cumulative dose response was used to obtain the maximum 
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enhancement that is obtained from the microbubble sample. Comparisons between the different 
surfactant mixtures and drug were then made to assess how the microbubble stability changes 
with changes in component mixture and presence of drug.  
For each time response, a dose on the rise was chosen from the dose response curve. This dose 
was then used to obtain how the enhancement varies as a function of time in the presence of an 
ultrasound beam. Thus obtained values were then normalized to comparison between samples. 
The half-life of the microbubbles for the chosen dose was then calculated from the graphs. 
3.4.3. Light Microscopy  
Light microscopy (Olympus IX71 fluorescence microscope) was used to a) obtain pictures of the 
microbubbles and b) assess cell viability using live-dead assays. The Images were obtained using 
SPOT Advanced software. 
3.4.4. Drug Quantification Using Fluorescence 
Intrinsic fluorescence of curcumin in certain organic solvent was used to quantify the amount of 
drug. Known amounts of microbubbles were taken in DMSO in 1.5 ml centrifuge. The mixture 
was vortexed for 30 seconds to break the bubbles and the tubes were spun to collect span 60 
particles at the top (surfactants form a foam-like structure on top with yellow colored solution at 
the bottom, containing curcumin). 150 µL of  liquid at the bottom was carefully pipetted into a 
96-well plate (opaque-plate) and fluorescence was read with excitation at 420 nm and emission at 
505 nm. Fluorescence of microbubbles with no drug was taken as baseline, as these do not 
fluoresce. The experiments were done in dark as curcumin is photo-sensitive and analyzed 
immediately. 
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3.5. Statistical Analysis 
All calculations were done using Microsoft Excel from the Office 2007 suite. Statistical analysis 
was done using 1-way ANOVA and 2-way ANOVA using Prism software version 5.03 
(GraphPad). 
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Chapter 4: Results and Discussion 
4.1. Ultrasound Contrast Agents Characterization 
4.1.1. Size Analysis 
Size analysis was done using Malvern Nano ZeatSizer. All 3 drug-free microbubbles were less 
than 3 µm in diameter which is ideal for an ultrasound contrast agent that can reach the 
capillaries.  
 
Figure 16: Effect of the wall component of the size of the microbubble. N=3 and error bars is standard error 
about mean. Regular refers to microbubbles with no drug. P>0.05 for all samples. 
In order that the microbubbles with the drug function pass the capillaries, these are required to be 
less than 3 µm in diameter. It was seen that addition of the drug to the microbubble core did not 
adversely increase the size of the microbubble. The size is also important as the response of 
microbubble to ultrasound wave also depends on it [105]. 
The sizes of all microbubbles including the drug loaded ones are individually presented in Figure 
17. When the layers do not separate distinctly, we have seen the presence of nano-sized bubbles 
in the samples (unpublished results from our lab).  
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Figure 17: Size of individual microbubble bubble types. N=3 and error bars indicate standard error about 
mean. P>0.05 for all samples.  
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. 
When all the microbubbles are compared with one another (Figure 18), it can be noted that all are 
less than 6 µm in diameter and the average size is between 2-3 µm. This shows that slight 
modification in the wall component does not alter the size of the microbubble significantly. 
 
Figure 18: Size of all microbubbles used. N=3, error bars is standard error about mean, p > 0.05  
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. 
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For microbubbles with increasing span 60 ratios, it was seen that 3 minutes of sonication at 110 
W did not produce any bubbles. Gravity separation at 4°C did not yield any bubbles after 3rd 
wash. Hence, changes in span 60 ratio was not used for further studies of drug loading as these 
would not function as ultrasound contrast agents. 
4.1.2. Acoustic Characteristics (In-vitro Testing) 
The acoustic testing was done as mentioned in the appendix B. Known doses were dispersed in 
50-ml PBS and the enhancement in ultrasound signal was recorded at a gain of 40 dB. ST68, the 
microbubble for which our lab has a patent was used as the standard against which STE681 was 
compared.  
4.1.2.1. Dose Response 
When the microbubbles were not loaded with drugs, the dose response for all 3 types was fairly 
similar (Figure 19). The doses for each microbubble type reach saturation close to a dose of 100 
µL It was seen with higher doses of SE61, shadowing occurs sooner than ST68 and STE681. 
Shadowing is a phenomenon where high concentration of microbubbles completely reflect the 
incident ultrasound beam. This phenomenon is similar to reduced visibility in a fog, and 
shadowing is an indication of what could be the maximum dose that can be administered for 
imaging modalities.  
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Figure 19: Enhancement of ultrasound signal for microbubbles with no drug loaded. N=3, error bars = standard 
error about mean, p > 0.05 
In accordance with the size analysis in the previous section, the dose responses for microbubbles 
containing the drug also did not vary much with respect to the original microbubbles with no drug 
(Figures 20A, 21A and 22A). When the drug was dissolved, the dose response again did not vary 
significantly from the regular bubbles (Figures 20B, 21B and 22B).  
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Figure 20: Dose response of ST68  A) Solid particle B) Dissolved drug. N=3, error bars = standard error about 
mean, p >0.05 
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. 
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Figure 21: Dose response of STE681  A) Solid particle B) Dissolved drug. N=3, error bars = standard error 
about mean, p >0.05 
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. 
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Figure 22: Dose response of SE61 dose response A) Solid particle B) Dissolved drug. N=3, error is standard 
error about mean, p >0.05 
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. 
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It is seen from the dose response that even in the presence of the drug, there is not much change 
in how enhancement varies with time for all three microbubble types. Furthermore it is also seen 
that the method used for loading the drug does not affect the dose response. 
4.1.2.2. Time Response 
Based on the dose responses obtained for each microbubble, a dose close to the linear range was 
chosen (choosing a dose along the plateau does not give a true ‘time’ response as it will only trace 
back along the dose response with time). To compare results, 50 µl/l was used for time response. 
This was found to be in the linear range of the dose response curve for all trials for all bubbles, 
with and without drug. The first comparison is between the three microbubble types in Figure 23. 
These do not have any drug loaded and is obtained by plotting the normalized enhancement as a 
function of time. The dose chosen for all of these time responses was 50 µl/l. Based on the traces 
for enhancement with time, the half-life for each bubble preparation was calculated and shown in 
Figure 24.. This is the time taken for the enhancement to drop to half of its initial value. For 
regular bubbles, highest stability was seen with SE61, and this is consistent with results obtained 
in our lab. STE681 has lower stability than SE61 but is similar to ST68 (Figure 23).  
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Figure 23: Time response of microbubbles with no drug. N=3, error bars is standard error about mean, p >0.05 
 
For the microbubbles which had the drug dissolved or loaded as solid particle, it was seen the 
half-life Figure 24 was only slightly lower than ST68 with no drug.  
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Figure 24: Half-life of microbubbles. Dose used is 50 ul/l. N=3, error bars is  standard error about mean, p >0.05 
 1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D 
have been used to indicate solid particle loading and dissolved drug respectively. 
When all the microbubbles were compared to each other, it was again seen that there were no 
significant changes in half-life due to the presence of the drug (p>0.05) (Figure 25). Comparisons 
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between half-life for same drug loading concentrations for different bubbles (e.g., 1-S for ST68, 
STE681 and SE61) were also not significant.  
 
Figure 25: Half life of all microbubbles. N=3, error bars = standard error about mean, p >0.05 
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. 
4.2. Drug Loading 
Amount of drug in the microbubbles was quantified using fluorescence of curcumin in DMSO. 
150 µl of  liquid was taken in a 96-well plate (as per the procedure mentioned in the methods 
section) and read with excitation at 420 nm and emission at 505 nm. The microbubbles which 
were not loaded with drug were taken as baseline for each type. The drug loading for each of the 
two methods and the type of microbubble is as follows. 
4.2.1. Loading curcumin as solid particle 
In this method, solid drug particles were dispersed in surfactant mixture prior to sonication and 
microbubbles were thus prepared. Curcumin is known to adhere to containers and in some trials 
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this and improper mixing was seen. Hence, prior to sonication the solution was stirred for a 
minute to disperse the drug in the solution.  
4.2.2. Loading curcumin as a dissolved drug  
Curcumin was also dissolved in a suitable solvent as an alternate method of loading. This was 
also done to uniformly distribute the drug prior to sonication. Several solvents were chosen and 
small amounts of Span 60, Tween 80, TPGS and curcumin were taken in the chosen solvent to 
check solubility with time. The same was also done for PBS which is the solvent for preparing 
microbubbles. The hypothesis was that such a solvent similar to PBS would not compromise the 
acoustic stability of microbubble by altering the structure of the wall of the microbubble. 0.1N 
NaOH had similar solvent characteristics as PBS and was used for dissolving the drug. Kurien et 
al, solubilized curcumin in 0.5N NaOH diluted it in PBS and used it to check for anti-oxidant 
activity [106]. The curcumin/turmeric remained soluble in all the dilutions used in the study done 
by Kurien Another reason that an organic solvent was not chosen was that it would require 
additional steps to remove traces and this might destroy bubbles. 
Table 3: Solubility of surfactant and drug 
 Surfactants 
 
Time 
(min) 
Span 60 
Tween 
80 
TPGS Curcumin 
PBS 
0 No No No No 
30 No No No No 
60 No No No No 
Acetone 
0 No No No Yes (yellow) 
30 No 
Yes 
(low) 
Yes Yes 
60 No Yes  Yes Yes 
0.1 N 
NaOH 
0 No No No Yes (deep red) 
30 No 
Yes 
(least) 
No Yes (deep red) 
60 No 
Yes 
(low) 
No Yes (deep red) 
Isopropanol 0 No No No No 
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30 No Yes No No 
60 No Yes No No 
Ethanol 
0 No No No Yes (slightly red) 
30 No 
Yes 
(low) 
Yes Yes (slightly red) 
60 No Yes Yes Yes (slightly red) 
 
The results for drug loading in microbubbles are summarized in Figures 26, 27 and 28 for each 
microbubble. There was an increase in the amount of drug with increased amounts of drug used, 
and this is seen in most studies with curcumin (dose dependent loading and effects) [107].  
 
Figure 26: Drug concentrations for both methods for ST68. N=3, error bars = standard error about mean. 
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. Solid particles: P < 0.001 for 1-S and 
3-S; p < 0.01 for 2-S and 3-S. Dissolved drug: p < 0.05 for 1-D and 3-D. p > 0.05 between S and D samples. 
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Figure 27: Drug concentrations for both methods for STE681. N=3, error bars = standard error about mean 
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. Solid particles: P < 0.001 for 1-S and 
3-S; p < 0.01 for 2-S and 3-S. Dissolved drug: p < 0.05 for 1-D and 3-D. p > 0.05 between S and D samples. 
  
 
Figure 28: Drug concentrations for both methods for SE681. N=3, error bars = standard error about mean 
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1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. Solid particles: p < 0.001 for 1-S and 
3-S and p < 0.05 for 2-S and 3-S. Dissolved drug: p < 0.01 for 1-D and 3-D. p < 0.05 for 1-S and 1-D; 2-S and 2-D 
and p < 0.01 for 3-S and 3-D. 
When all the drug concentrations for both methods were compared (Figure 29), a complicated 
analysis of significance arose. The p values have been summarized in the table following the 
Figure. Unpublished results in our lab, have shown that ST68 has lower drug payload when 
compared to SE61. When compared to SE61, STE681 shows no significance (except for 2-S).  
  
Figure 29: Drug concentrations for both methods for all microbubbles. N=3, error bars = standard error about 
mean. Statistical analysis in table 4. 
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively. 
Table 4: Statistical analysis for drug loading comparing all 3 types of microbubbles 
 ST68 vs SE61 STE681 vs SE61 ST68 vs STE681 
1-S P<0.001 P > 0.05 P > 0.05 
2-S P<0.001 P<0.01 P < 0.05 
3-S P<0.001 P > 0.05 P<0.001 
1-D P > 0.05 P > 0.05 P<0.01 
2-D P < 0.05 P > 0.05 P<0.01 
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3-D P<0.001 P > 0.05 P<0.001 
 
Efficiency of drug loading in the microbubbles was also calculated. Approximately 10 ml of 
microbubbles are obtained at the end of each trial and these are diluted 1:1 in PBS to obtain the 
working solution. We start with 50 ml of surfactant mixture in which known amounts of drug are 
dispersed/dissolved. The hypothesis is that there is no free drug in the buffer, and they are all 
associated with the microbubbles. The efficiency is calculated using the following formula: 
Drug encapsulation e34icienc5 =  
[Amount o3 drug in microbubbles (ug)/
Initial amount used (ug)]
 × 100 
When the drug loading graph is plotted in terms of efficiency (Figure 30), it can be seen that 
lower drug amounts are more efficiently loaded into the microbubbles and for higher amounts, 
more drug is lost during washes with PBS. The efficiency is highest for SE61 when the initial 
loading concentration is low. For dissolved curcumin, highest efficiency is for STE681. 
 
Figure 30: Loading efficiency of curcumin for all microbubbles. Statistical analysis in table 5. 
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1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S and D have 
been used to indicate solid particle loading and dissolved drug respectively 
Table 5: Statistical analysis comparing all 3 types of microbubbles. n=3, error bars = standard error about 
mean. 
 ST68 vs SE61 STE681 vs SE61 ST68 vs 
STE681 
1-S P<0.001 P > 0.05 P<0.001 
2-S P<0.001 P<0.01 P < 0.05 
3-S P<0.001 P > 0.05 P<0.01 
1-D P > 0.05 P > 0.05 P<0.001 
2-D P < 0.05 P > 0.05 P<0.01 
3-D P > 0.05 P > 0.05 P < 0.05 
 
4.2.3. Freeze-dried STE681 
Freeze-drying is a process that is normally used in pharmaceutical formulations to deliver 
drugs, proteins in a solid form. In our lab, the contrast agent ST68 has been successfully 
freeze-dried [108] using glucose as a lyoprotectant. STE681 was freeze-dried using 
glucose as a lyoprotectant using the procedure detailed in the Appendix. This was done to 
preserve the echogenicity on storage. Most pharmaceuticals and contrast agents currently 
available on the market are formulated as freeze-dried, sterile products sealed in vials and 
these are reconstituted with sterile water or buffer prior to use. The same parameters of 
size, acoustic stability and drug amounts were also calculated for solid particle loading of 
STE681. There was no significant change in dose-response for the freeze-dried and non 
freeze-dried samples of STE681 (figure 32).  
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Figure 31: Dose response of freeze-dried STE681. N=3, error bars = standard error about mean 
1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S indicates 
solid particle loading , p > 0.05 when compared to non-freeze dried STE681. 
Some bubbles are destroyed during the process of freeze-drying and hence, a higher dose is 
needed for the time response. For the freeze-dried STE681, 100 µl/l of reconstituted agent was 
used for the time response. The decrease in the half life when compared to corresponding non 
freeze-dried STE681 samples can be attributed to increased sensitivity of the freeze-dried 
microbubbles to ultrasound (figure 33). 
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Figure 32: Half-life of freeze-dried STE681 compared to non freeze-dried STE681. N=3, error bars = standard 
error about mean, p > 0.05  
The amount of drug in the microbubbles after it is reconstituted was also quantified using the 
fluorescence method (figure 34). It was seen that there was no significant changes between the 
freeze-dried and non freeze-dried samples for all three concentrations of initial drug.  
 
Figure 33: Drug concentrations of freeze-dried STE681 compared to non freeze-dried STE681. N=3, error bars 
= standard error about mean, p > 0.05 
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1, 2 and 3 corresponds to 100 µM, 250 µM and 500 µM initial curcumin concentrations. Alphabets S indicates 
solid particle loading. 
4.3. Cell Studies 
Due to the various molecular mechanisms by which curcumin acts, 2 breast cancer cell which 
respond differently to the drug lines were chosen for cell studies. Preliminary studies were 
conducted to test the effects of drug loaded microbubbles on the 2 cell lines. 
4.3.1. MDA-MB-231 Breast Cancer Cell Line 
Passages 8-10 were used for MDA-MB-231 cell line and LIVE/DEAD assay was done to check 
cell death in the presence and absence of curcumin. Most cell studies using curcumin are done 
between 48-72 hours and hence the same time frame was followed and all results are reported at 
the end of 48 hrs because controls were found to be >90% confluent at this time point (Figure 
34). 1:11 dilution of microbubbles: media was used for the cell studies. It was seen that at this 
dilution, the cells disintegrated completely after 48 hours. This was seen with microbubbles were 
loaded with drug and for microbubbles with no drug (Figures 35 and 36). In a paper by Gianasi et 
al, rat erythrocytes were incubated with span 60 niosomes for 1 and 24 hrs [16]. 40% hemolysis 
was seen at 24 hrs for concentration of 500 µg/ml niosomes. Tween 80 does not show any 
hemolytic activity [109] but is shown to cause cellular damage (lysis) at dilutions between 1:10 
and 1:100 [19].  
A complete toxicology test has been conducted for ST68 and this shows no toxicity of the 
microbubble when injected in-vivo [110]. Hence, we need a better method to see the effect of the 
microbubbles and drug on the cell lines.  
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Figure 34: MDA-MB-231 Control cells after 48 hrs (Magnification: 20X). 
 
Figure 35: MDA-MB-231 cells after incubation with ST68 microbubbles. Left: No drug, Right: 3-S. 
Magnification 20X 
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Figure 36: MDA-MB-231 cells after incubation with SE61 microbubbles. Left: No drug, Right: 3-S. 
Magnification 20X 
4.3.2. MCF7 Breast Cancer Cell Line 
Passages 17-20 were used for MCF-7 cell lines and LIVE/DEAD assay was used to quantify cell 
death after 48 hours of treatment. Opticell cassettes or 6-well plates were used for the cell study.  
For the control, which were cells growing in media with no ultrasound or drug; the morphology 
of the cell was maintained after 48 hrs. The cells grew uniformly on the surface to reach 90% 
confluency (Figure 37). 
55 
 
 
Figure 37: Bright-field microscope image of control (MCF-7 cells, magnification 20X) 
When the cells were incubated with microbubbles containing the drug (3-S was used for cell 
study), at the end of 48 hrs the cells looked round which indicates that they are no longer attached 
(Figure 38). There were also fragments in the media that can be disintegrated bubbles. 
LIVE/DEAD assay was conducted at the end of 48 hrs, and few live cells were seen (Figure 39).  
As with the MDA-MB-231 cells, the cellular fragments and lumping seen in Figure 38 could be 
due to high concentration of bubbles that might cause toxicity to the cells. Antibiotic was used in 
the medium, and careful inspection of the samples was done to rule out any bacterial 
contamination that can cause cell death. The samples were also done in triplicate with same 
results. As with the previous cell line, we conclude that a better method is necessary to test the 
effects of drug on cells.  
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Figure 38: ST68 with drug; no ultrasound (MCF-7 cells, magnification 20X) 
 
 
Figure 39: Microbubbles with drug, no US. (MCF-7 cells). Green: Live, Red: Dead 
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Chapter 5: Conclusions 
It has been shown in this work that a hydrophobic, insoluble drug like curcumin can be 
incorporated in a microbubble, which is an ultrasound contrast agent. The goal of the presented 
work was to load the drug without compromising on the acoustic property of the microbubble. 
Two methods were used, one where the drug was a solid particle and another where the drug was 
dissolved in a suitable solvent.  
All three types of microbubbles, ST68, STE681 and SE61 were used for studying acoustic 
properties and drug loading and statistical analysis was done for each. Each type had the same 
molar ratio of span 60 with varying ratios of Tween 80 and TPGS (changes to span 60 ratio did 
not yield microbubbles and was not included for further experiments). The sizes of all 
microbubbles were less than 6 µm in diameter which is ideal for ultrasound contrast agent (most 
having an average diameter close to 3 µm). One formulation of the microbubble was also freeze-
dried and reconstituted, while the other 2 types were tested for efficacy on two breast cancer cell 
lines, MCF-7 and MDA-MB-231. 
It was seen that the drug can be incorporated into the microbubbles using both methods. Higher 
drug was found within the microbubble when higher initial amounts of drug were used for both 
methods. When the drug loading was analyzed in terms of efficiency, lower initial concentrations 
resulted in better efficiency. Between the three types, ST68 showed the least drug loading and as 
well as efficiency.  However, the amounts obtained were too low for use as a therapeutics 
formulation.   
Cell-death was seen for both cell lines after a period of 48 hours. This was seen by a change in 
the morphology of the cell with time, when compared to control cells. ST68 does not show 
toxicity when injected in-vivo, and hence we conclude that another method of testing effect of 
drug on cells becomes necessary. 
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Chapter 6: Recommendations 
The fact that the acoustic stability is not affected by presence of drug indicates that other 
techniques such as ligand-attachments, co-administration of drug can be achieved with this 
microbubble-drug combination.  
Cell death was seen at 24 and 48 hrs for breast cancer cells, and this might be due to the 
surfactants used, that may interact with the cell membranes. A study can be done to analyze how 
the cells interact with the surfactant to rule out surfactant induced toxicity in vivo.  
For the cell studies, antibiotics were used to grow cells without bacterial contamination. 
Sterilizing the microbubbles prior to cell studies is another study currently underway in our lab 
using plasma sterilization.  
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Appendix 
Appendix A: List of Nomenclature Used 
Table 6: Microbubble types 
Name of 
microbubble 
Molar  ratio of surfactant 
Span 60 Tween 80 tpgs 
ST68 80 20 0 
STE681 80 10 10 
SE61 80 0 20 
 
Table 7: Drug concentrations and loading method 
Initial Concentration Solid Particle Dissolved Drug 
100 µM 1-S 1-D 
250 µM 2-S 2-D 
500 µM 3-S 3-D 
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Appendix B: Standard Operating Procedures 
B.1. Microbubble Preparation  
1.  To a clean 300 ml beaker, add 1.5g sodium chloride and calculated amounts of Span60, 
Tween80 and/or TPGS in 50 ml PBS  (pH 7.4). Also add a stir-bar to the beaker. 
Table 8: Amount of surfactants used for each microbubble 
 Span 60 (g) Tween 80 (ml) TPGS (g) 
ST68 1.464 1.12 0 
STE681 1.464 0.56 0.65 
SE61 1.464 0 1.288 
70-15-15 1.28 0.83 0.97 
60-20-20 1.1 1.12 1.288 
 
2. Cover the beaker with aluminium foil and attach a 1 inch  piece of autoclave tape. Heat the 
solution till the Tween and/or TPGS dissolve completely (Care must be taken that the solution 
does not boil vigorously). 
3. Autoclave this mixture for 30 min to reduce the particle-size of span 60. 
4. Allow the mixture to then cool to room-temperature while stirring constantly. Also put 
separation funnel and PBS in the 4°C refrigerator to keep them cold prior to sonication. 
5. Remove the magnetic stir-bar and prepare the solution for sonication. Place the beaker in ice 
and purge the solution with PFC gas to degas the mixture for 15 sec at 50 ml/min  
6. With continuously purging of a stream of PFC gas at 50 ml/min (flow rate?), sonicate the 
mixture for 3 min at 110 W using  Misonix Inc. CL4 tapped horn probe with 0.5” tip, 
Farmingdale, NY. 
7. When this is complete, collect the cold PBS and the separation funnels, and add the sonicated 
mixture to the separation funnel. Wash the beaker with 50 ml of cold PBS and pour this into the 
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separation funnel. Place the separation funnel back in the fridge till distinct foam-liquid layer 
forms (this time varies for each microbubble type with SE61 having the longest time (45 minutes) 
and ST68 the shortest (20 minutes)). Discard 50 ml from the first wash, and repeat the wash 
procedure 2 more times. 
8. At the end of the 3rd wash, discard all clear liquid and collect the intermediate layer containing 
the microbubbles in vacutainers. Typically, this is done by taking the microbubble samples in 
syringes of 10 ml with a 20G needle and the sample is injected into sterile vacutainers. 
9. The working solution is a 1:1 dilution of microbubbles in membrane-filtered PBS (to prevent 
impurities and contaminants in sample). 
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B. 2. Size Analysis 
1.  Size analysis was done using Zetasizer nano ZS (Malvern Inst., Worcestershire, UK). 
2. 50 µl of 1:1 diluted microbubbles is dispersed by shaking gently in 950 µl PBS in a tapered 
cuvette. The cuvette is then placed in the slot of the instrument. 
3. The appropriate Measurement SOP was chosen from the dropdown in the Zeta-sizer software 
GUI and the measurement taken three times.  
4. The z-average and PDI of the sample was noted. 
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B. 3. Enhancement (Dose and Time Response) 
1. Initial set-up for the acoustic testing of microbubbles is to set the function generator to PRF to 
100 Hz, energy to 1, and damping to 3. A 5072 pulser-receiver (Waltham, MA) is used to 
generate acoustic pressures with a pulse repetition frequency (prf) of 100 Hz. Oscilloscope 
(Lecroy 9350 A, Chestnut Ridge, NY) is set to 1 µs and 100 mV.  
2. Fill the inner vessel with 50 ml of 37 oC membrane-filtered PBS and add stir bar. The 
transducer is focused through the transparent window till a signal is seen at 20 dB gain for 20 
µsec delay. 
3. Use a 5 MHz transducer, set the gain initially to 20 dB and find the optimal angle and distance 
for transducer. The cover of the tank was fitted with an x–y positioning system (Edmund 
Scientific, Barrington, NJ) to mount and position the ultrasonic transducers. Use 40 dB gain to 
measure.  
4. Create a folder with sample details to save the data. Open the LabVIEW (National Instruments, 
Austin, TX) program in the computer to record data (Ultrasound folder->main program->main 
ultrasound program.vi). Set Cur Dir to folder created. 5. Make the baseline for the sample and 
press acquire. Wait until the saving is done (it is advisable that the voltage reading is less than 4 
mV for the baseline).  
6. In analyze data tab, set the total dose added  
7. Add sample to the sample chamber using a 100 µl pipette and press acquire. Wait until the 
saving is done and add the next dose. 
8. Repeat this till the desired total dose is obtained (in most cases, this is the dose where 
shadowing effect begins to affect enhancement).  
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9. Export the data (calculated and raw) to folder created for the sample in step 4 and save. 10. For 
the time response, select a dose on the rise of the dose response curve, before the peak is reached, 
and set the time response to 10-15 min (set interval to 1 min between samples). 
11. Make baseline again and save in a new folder. Add the dose from previous step and press 
acquire. 
12. Export the data to the folder as mentioned in step 9. 
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B. 4. Freeze-drying protocol 
1. Follow SOP ST68 until the last step (do not dilute 1:1 with PBS (1x)). Pipette desired amount 
of ST68 into lyophilization vials (West Pharmaceutical Services, Lionville, PA)  (at least 1mL, 2 
ml is recommended). 
2. Pipet equal volume of 200mM Glucose solution (in PBS) or selected lyoprotectant 
3. Quick freeze in liquid nitrogen for 5 minutes. Place lyophilization septum stopper (West 
Pharmaceutical Services)  on vial to its first groove and let sit at -80°C until ready or place right 
onto previously chilled (-80°C) lyophilizer shelf. 
4. Freeze dry for 15 to 18 hours. While the vials are still under vacuum lower piston on the 
lyophilizer to close  the septum stopper onto the vial Raise piston and slowly release the vacuum 
5. Wrap a piece of parafilm around the seam where the septum stopper meets the vial to prevent 
leaks.  
6. Immediately, add PFC gas into the vial through the septum using a 25.5G G needle attached to 
the gas tank and allow gas to flow at 6 (50 ml/min) initially and then lower to 4 (20 ml/min) until 
full minus the reconstitution volume (volume of bubbles originally added) 
7. Reconstitute just prior to use by injecting a volume of DI water equal to the original sample 
volume prior to freeze drying and shake until particles are suspended.  Add PBS if need to dilute. 
 
B. 5. Cell Studies 
MCF-7 cells were cultured in DMEM media (89% DMEM, 10% FBS and 1% antibiotic) from 
passages 16-19. MDA-MB-231 cells were cultured in RPMI 1640 media (94% RPMI, 5% FBS 
and 1% antibiotic). Cells were grown in either 6 well plates or Opticells. 
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The LIVE/DEAD assay was preformed as instructed by the manufacturer. The protocol followed 
for the same is as follows: 
1. Prepare a working solution of the mixed dyes (2 µl of component A and 2 µl of component B 
in 1 ml of HBSS). Mix by vortexing or pipetting up and down. Store at 4 °C and protected from 
light. 
2. Pipet 105 - 106 cells from petridish to centrifuge tubes (preferably made of polypropylene) and 
centrifuge. 
3. Remove medium completely and loosen the pellet by tapping the side of the centrifuge tube. 
Add 200 µl of diluted dye and complete resuspension. 
4. Incubate at room temperature for 15 min in complete darkness. Centrifuge the cells again, and 
discard the supernatant.  
5. Resuspend the cells in minimal volume of fresh HBSS. Add $% glutaraldehyde to yield a cell 
density of less than 106 cells/ml. 
6. Incubate the cells in fixative for atleast 15 min before observing under a microscope. (The cells 
can be observed for their staining pattern after several hours if it is stored at 4 °C away from 
light). 
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Appendix C: Conjugation of Doxorubicin to TPGS 
Doxorubicin is an anthracycline drug that is widely used for cancer therapy. Doxorubicin is 
known to be highly cardiotoxic [111] and hence several modifications are done in drug delivery 
applications. One such method was published by Cao et al, in 2008, in which doxorubicin was 
conjugated to TPGS polymer [31]. The conjugation procedure as followed by the authors was 
used to prepare TPGS-doxorubicin conjugates that could be used to prepare microbubbles. In 
brief, the procedure consists of activating TPGS (TPGS-SA) using succinic anhydride in the 
presence of DMAP (4-dimethylaminopyridine) under an atmosphere of nitrogen for 24 hr. This 
activated TPGS is then conjugated to doxorubicin in the presence of DCC (N,N'-
dicyclohexylcarbodiimide), TEA (triethyl amine) in DMSO under an atmosphere of nitrogen for a 
further 24 hr. The mixture is then dialyzed using a MWCO 1000 membrane to remove 
unconjugated doxorubicin.  
After the first step of activating TPGS (done in the lab of Dr. Anthony Addison, Department of 
Chemistry, Drexel University), mass spectroscopy analysis was done at the Department of 
Chemistry, Drexel University. It was seen from the analysis that the TPGS was not activated by 
the protocol followed (Figure 40). 
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Figure 40: Mass-Spec Analysis. Top: TPGS-SA, Bottom: TPGS 
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Appendix D: Experiments to Investigate the Particle-Stabilized Theory 
Unpublished results in our lab have indicated another theory for the stability of microbubbles 
besides the one published in literature [112]. This theory is based on Pickering’s theory published 
in 1907 which refers to foams and emulsions which consist of drops or bubbles that are stabilized 
by small solid particles (in this case span 60) attached to the bubble surface [113]. The schematic 
illustration of how such gas bubbles are stabilized by solid particles in given in the Figure below 
[114]. 
 
Figure 41: Particle stabilized theory. Solid particles stabilize bubbles by forming a layer at the water-oil 
interface [76] 
 
D.1.  The use of gold nanoparticles 
D.1.1 Preparation of gold nanoparticles using citrate synthesis. 
To investigate the particle-stabilized theory for microbubbles (proposed microbubble-structure 
theory, unpublished results), gold nanoparticles were synthesized using citrate synthesis method, 
in order to see if they could be used in place of Span [115]. In this method, gold nanoparticles are 
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prepared by reducing HAuCl4.  In brief, 20 ml of 1mM HAuCl4 is boiled and 1 ml of 1% sodium 
citrate solution is added. The gold sol gradually forms as the citrate reduces the gold (III). The 
heating is continued till a deep red color is obtained which indicates colloidal gold (small 
nanoparticles of gold are red). A layer of absorbed citrate anions on the surface of the 
nanoparticles keep the nanoparticles separated.  
D.1.2. Use of gold particles to make microbubbles 
These gold nanoparticles were 30-35 nm in diameter when measured using the Zetasizer. These 
were used instead of span60 to investigate the particle stabilized theory. However, there were 
issues with the experiment design. The buffer normally used is PBS, and in the presence of strong 
anions, the gold nanoparticles coagulate. When the PBS was replaced with DI water and the 
experiment was repeated, it was seen that most of the gold nanoparticles were lost in the 3 washes 
(indicated by red color of wash liquid). This can be attributed to the size of the gold nanoparticle 
as it is much smaller compared to span60. A new protocol to control the size of the gold 
nanoparticle and prepare bigger particles using the same citrate synthesis is now available and the 
experiment can be repeated to prove particle-stabilized theory.  
D. 2. Use of liquid/liquid surfactants to make microbubbles 
Other chemicals that were used to investigate this theory include IGEPAL CA720 and IGEPAL 
CO890 (Sigma Aldrich) compounds which have a PEG chain, but although all properties of 
span60 and IGEPAL were comparable (a table comparing them would be great) , IGEPAL is 
completely soluble in PBS owing to a PEG chain in its structure. Sonicating a mixture where span 
60 is replaced by IGEPAL compounds in the same molar ratios as used for ST68 yielded foam 
that did not form microbubbles.  
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Figure 42: Structures of IGEPAL. Left: CA720, Right: CO890 
 
D.3. Use of curcumin particles to replace Span in making microbubbles 
Curcumin was also seen as a potential candidate to substantiate the particle-stabilized theory. 
However, when curcumin (molecular weight 368.3) was substituted for span60, the higher 
hydrophobicity of curcumin resulted in an uneven mixture that clogged the pore of the separation 
funnel as the curcumin did not integrate into the microbubble structure.  
D.4. Conclusions 
While the observation that soluble surfactant IGEPAL did not make microbubbles with Tween 
80, the fact that hydrophobic particles used here (gold and curcumin) did not form stabilized 
bubbles, it can be concluded that a hydrophobic particle per se is not sufficient to create stabilized 
micobubbles with Tween.  It must be concluded that if this theory is correct, both the size and 
hydrophobicity of the particle compared to the Tween/TPGS is a crucial element in allowing 
stabilized bubbles to form. 
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